Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies

• US 20030118577A1
• Filed: 02/03/2003
• Published: 06/26/2003
• Est. Priority Date: 03/28/2000
• Status: Abandoned Application

• Current Assignee: Universite Rene Descartes
• Original Assignee: Universite Rene Descartes
• Inventors: Ferret, Pierre-Jacques, Weill, Bernard, Batteux, Frederic
• Application Number:
  US10/240,270
• Publication Number:
  US 20030118577A1
• Time in Patent Office: Days
• US Class Current: 424/94.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 38/446 Superoxide dismutase (1.15)
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: C12Y 111/01006 Catalase (1.11.1.6)
• CPC Class Codes: C12Y 111/01009 Glutathione peroxidase (1.11.1.9)
• CPC Class Codes: C12Y 115/01001 Superoxide dismutase (1.15.1.1)

Abstract

The invention concerns the use of a compound having a superoxide dismustase activity, in particular a non-peptide analogue of the superoxide dismutase to obtain a medicine for preventive or curative treatment of hepatocellular insufficiency. Said medicine can be used in particular for treating hepatocellular insufficiencies of toxic or viral origin.

Claims

1. The use of a manganese superoxide dismutase (MnSOD) mimetic for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency.

2. The use as claimed in claim 1, characterized in that said MnSOD mimetic possesses, in addition, a catalase activity and/or a glutathione peroxidase activity.

3. The use as claimed in either of claims 1 and 2, characterized in that said MnSOD mimetic is MnTBAP.

4. The use as claimed in any one of claims 1 to 3, characterized in that said MnSOD mimetic is used for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency of toxic origin.

5. The use as claimed in claim 4, characterized in that said MnSOD mimetic is used for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency induced by acetaminophen.

6. The use as claimed in any one of claims 1 to 3, characterized in that said MnSOD mimetic is used for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency resulting from Fas-dependent apoptosis of the hepatocytes.

7. The use as claimed in claim 6, characterized in that said MnSOD mimetic is used for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency of viral origin.

8. The use as claimed in any one of claims 1 to 4, characterized in that said MnSOD mimetic is used for producing a medicament intended for the preventive or curative treatment of hepatocellular insufficiency induced by alcohol.

9. The use as claimed in any one of claims 1 to 8, characterized in that said MnSOD mimetic is used for producing a medicament intended for the treatment of hepatocellular insufficiency manifesting itself in the form of fulminant hepatitis.

10. The use as claimed in any one of claims 1 to 9, characterized in that said MnSOD mimetic is used for producing a medicament intended for a preventive treatment.

11. The use as claimed in any one of claims 1 to 9, characterized in that said MnSOD mimetic is used for producing a medicament intended for a curative treatment.

12. The use as claimed in claim 10, characterized in that said medicament is formulated to allow the administration of an MnSOD mimetic dose of between 0.1 and 10 mg/kg/day.

13. The use as claimed in claim 11, characterized in that said medicament is formulated to allow the administration of an MnSOD mimetic dose of between 5 and 50 mg/kg/day.

14. The use of an MnSOD mimetic for protecting hepatic grafts during their preservation.